Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 179

1.

Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.

Liu H, Hu Y, Rimoldi R, Von Hagt C, Khong EWC, Lee N, Flemming S, Spencer A, Dear AE.

Oncol Lett. 2019 Feb;17(2):2543-2550. doi: 10.3892/ol.2018.9841. Epub 2018 Dec 17.

2.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
3.

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Kumar SK, Grzasko N, Delimpasi S, Jedrzejczak WW, Grosicki S, Kyrtsonis MC, Spencer A, Gupta N, Teng Z, Byrne C, Labotka R, Dimopoulos MA.

Br J Haematol. 2019 Feb;184(4):536-546. doi: 10.1111/bjh.15679. Epub 2018 Nov 20.

PMID:
30460684
4.

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis.

Weisel K, Sonneveld P, Spencer A, Beksac M, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A.

Leuk Lymphoma. 2019 Jan;60(1):151-162. doi: 10.1080/10428194.2018.1466392. Epub 2018 Nov 8.

PMID:
30407092
5.

Contemporary analysis of functional immune recovery to opportunistic and vaccine-preventable infections after allogeneic haemopoietic stem cell transplantation.

de Silva HD, Ffrench RA, Korem M, Orlowski E, Curtis DJ, Spencer A, Avery S, Patil S, Morrissey CO.

Clin Transl Immunology. 2018 Oct 5;7(10):e1040. doi: 10.1002/cti2.1040. eCollection 2018.

6.

meta-C-H arylation of fluoroarenes via traceless directing group relay strategy.

Font M, Spencer ARA, Larrosa I.

Chem Sci. 2018 Jul 25;9(35):7133-7137. doi: 10.1039/c8sc02417k. eCollection 2018 Sep 21.

7.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV.

Haematologica. 2018 Sep 20. pii: haematol.2018.194118. doi: 10.3324/haematol.2018.194118. [Epub ahead of print]

8.

Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation.

Portillo-Lara R, Spencer AR, Walker BW, Shirzaei Sani E, Annabi N.

Biomaterials. 2018 Aug 4. pii: S0142-9612(18)30564-7. doi: 10.1016/j.biomaterials.2018.08.010. [Epub ahead of print]

PMID:
30201502
9.

Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5).

Chen T, Reich NW, Bell N, Finn PD, Rodriguez D, Kohler J, Kozuka K, He L, Spencer AG, Charmot D, Navre M, Carreras CW, Koo-McCoy S, Tabora J, Caldwell JS, Jacobs JW, Lewis JG.

J Med Chem. 2018 Sep 13;61(17):7589-7613. doi: 10.1021/acs.jmedchem.8b00308. Epub 2018 Aug 24.

PMID:
30141927
10.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

PMID:
30098165
11.

Mining the Plasma Cell Transcriptome for Novel Cell Surface Proteins.

Trezise S, Karnowski A, Fedele PL, Mithraprabhu S, Liao Y, D'Costa K, Kueh AJ, Hardy MP, Owczarek CM, Herold MJ, Spencer A, Shi W, Willis SN, Nutt SL, Corcoran LM.

Int J Mol Sci. 2018 Jul 24;19(8). pii: E2161. doi: 10.3390/ijms19082161.

12.

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma.

Mithraprabhu S, Sirdesai S, Chen M, Khong T, Spencer A.

Int J Mol Sci. 2018 Jun 24;19(7). pii: E1858. doi: 10.3390/ijms19071858.

13.

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.

Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28.

PMID:
29910180
14.

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G.

J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31.

PMID:
29851546
15.

Analysis of Circulating Tumor DNA.

Mithraprabhu S, Spencer A.

Methods Mol Biol. 2018;1792:129-145. doi: 10.1007/978-1-4939-7865-6_9.

PMID:
29797256
16.

DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma.

Yuen HLA, Low MSY, Fedele P, Kalff A, Walker P, Bergin K, Coutsouvelis J, Grigoriadis G, Spencer A.

Leuk Lymphoma. 2018 Dec;59(12):2842-2846. doi: 10.1080/10428194.2018.1454595. Epub 2018 Apr 4.

PMID:
29616871
17.

Critical review of the validity of patient satisfaction questionnaires pertaining to oral health care.

Nair R, Ishaque S, Spencer AJ, Luzzi L, Do LG.

Community Dent Oral Epidemiol. 2018 Aug;46(4):369-375. doi: 10.1111/cdoe.12377. Epub 2018 Mar 30.

PMID:
29603328
18.

Dental knowledge and dental service utilization: A 2-year follow-up study.

Amarasena N, Spencer AJ, Roberts-Thomson KF, Brennan DS.

Community Dent Oral Epidemiol. 2018 Aug;46(4):336-342. doi: 10.1111/cdoe.12371. Epub 2018 Feb 20.

PMID:
29461636
19.

Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.

Rodda AE, Parker BJ, Spencer A, Corrie SR.

ACS Sens. 2018 Mar 23;3(3):540-560. doi: 10.1021/acssensors.7b00953. Epub 2018 Feb 23.

PMID:
29441780
20.

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.

Quach H, Benson S, Haysom H, Wilkes AM, Zacher N, Cole-Sinclair M, Miles Prince H, Mollee P, Spencer A, Joy Ho P, Harrison SJ, Lee C, Augustson B, Daly J.

Intern Med J. 2018 Feb;48(2):210-220. doi: 10.1111/imj.13707. Review.

PMID:
29415351

Supplemental Content

Loading ...
Support Center